Drugs / Piperacillin-tazobactam
Piperacillin-tazobactam
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02466438 | Jan 2016 → Dec 2018 | infectious disease | St. Justine's Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03862079 | Jun 2020 → Dec 2021 | graft versus host disease | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07575009 | Apr 2026 → Dec 2028 expected | infectious disease | Tampere University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT03269994 | Nov 2017 → Jan 2025 | malignant pancreatic neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT01577368 | May 2011 → Jan 2014 | Pseudomonas aeruginosa infectious disease | Andalusian Public Foundation for Health Research in Seville | Completed | No outcome recorded |
| Phase 45 trials · 2 missed | ||||||
| Phase 4 | NCT06929702 | Apr 2025 → Oct 2027 expected | — | University Hospital, Ghent | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06690905 | Feb → Sep 2025 | infectious disease, obesity disorder | CR-CSSS Champlain-Charles-Le Moyne | Completed | No outcome recorded |
| Phase 4 | NCT06293677 | Mar 2024 → Mar 2026 overdue | neutropenia | Centre Hospitalier Universitaire Vaudois | Recruiting | No outcome recorded |
| Phase 4 | NCT02437045 | Apr 2015 → Dec 2020 | bacterial infectious disease | The University of Queensland | Completed | Missed primary |
| Phase 4 | NCT02176122 | Feb 2014 → Jul 2017 | bacterial infectious disease | The University of Queensland | Terminated | Missed primary |
| Phase not applicable5 trials · 1 missed | ||||||
| — | NCT07620223 | May 2026 → Dec 2028 expected | hepatobiliary disorder | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| — | NCT04276480 | Feb 2022 → Apr 2024 | bacterial infectious disease | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT01714557 | Sep 2012 → Sep 2014 | disease related to hematopoietic stem cell transplant, neutropenia | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT01290003 | Jun 2010 → Jan 2011 | neonatal sepsis | Lady Hardinge Medical College | Completed | Missed primary |
| — | NCT00153634 | Mar 2004 → Nov 2007 | chronic bronchitis, cystic fibrosis | Seattle Children's Hospital | Completed | No outcome recorded |
| Comparator or background therapy19 trials | ||||||
| Phase 1 | NCT00873327 Comparator | Oct 2009 → Jul 2010 | infectious disease with sepsis | Phillip Brian Smith | Completed | No outcome recorded |
| Phase 2 | NCT07318584 Comparator | Mar 2026 → Feb 2028 expected | escherichia coli discitis | Oregon Health and Science University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04983901 Comparator | Sep 2021 → Oct 2023 | cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03078010 Comparator | Feb 2017 → Feb 2027 expected | neutropenia | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04879030 Background | Jan → Aug 2020 | chronic obstructive pulmonary disease | Haiphong University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2/3 | NCT02753946 Comparator | Apr 2016 → Jan 2017 | acute pyelonephritis | Nabriva Therapeutics AG | Completed | Met primary |
| Phase 2/3 | NCT01994993 Comparator | Dec 2013 → Jan 2017 | — | Michael Cohen-Wolkowiez | Completed | No outcome recorded |
| Phase 3 | NCT06123169 Comparator | Jul 2026 → Sep 2028 expected | — | University Hospital, Rouen | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03582007 Comparator | Oct 2018 → Jul 2019 | pneumonia | Polyphor Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03409679 Comparator | Mar 2018 → Jul 2019 | pneumonia | Polyphor Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT02820987 Comparator | Sep 2016 → Oct 2018 | infectious disease with sepsis | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 3 | NCT02473263 Comparator | May 2016 → Feb 2019 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT07590648 Background | Jun 2026 → Jul 2028 expected | bacterial infectious disease, childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm, neutropenia | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06712641 Comparator | Apr 2026 → Jun 2028 expected | infectious disease with sepsis | University Hospital, Akershus | Recruiting | No outcome recorded |
| Phase 4 | NCT06954129 Comparator | Jan 2026 → May 2029 expected | acute kidney injury | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 4 | NCT05977868 Comparator | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT05094154 Comparator | Nov 2021 → Oct 2022 | acute kidney injury, infectious disease with sepsis, poisoning | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01667094 Comparator | Sep 2012 → Jul 2017 | cystic fibrosis | The Alfred | Unknown | No outcome recorded |
| — | NCT06080698 Comparator | Feb 2024 → May 2027 expected | gram-negative bacterial infections | Johns Hopkins University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piperacillin-tazobactam | “Beta lactam antibiotics for non-ESBL E. coli infections include preferred ceftriaxone or alternative cephalosporins (cefepime, ceftazidime), penicillins...” NCT07318584 ↗35“The beta-lactam antibiotics with activity against gram-negative bacilli in this study included piperacillin-tazobactam, ticarcillin-clavulanate, imipenem-cilastin, meropenem,...” NCT04879030 ↗ “Drug stop within 24 hours after randomization:Piperacillin-tazobactam, amikacin, meropenem, cefepime, ceftazidime, vancomycin, teicoplanin, ciprofloxacin, levofloxacine and...” NCT07590648 ↗ “various combination of antibiotics (ampicillin, metronidazole, clindamycin, piperacillin-tazobactam, gentamicin)” NCT01994993 ↗ “The antibiotics used in the study are benzylpenicillin, cloxacillin, piperacillin-tazobactam and vancomycin.” NCT07575009 ↗ “Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin” NCT03409679 ↗ “meropenem, oritavancin, oxacillin, penicillin, piperacillin-tazobactam, tigecycline, vancomycin” NCT05977868 ↗ “Includes antibiotics such as ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem.” NCT06080698 ↗ “piperacillin-tazobactam, an extended-spectrum penicillin with beta-lactamase inhibitor” NCT05094154 ↗ “amoxicillin-clavulanic acid, piperacillin-tazobactam, meropenem treatment” NCT06929702 ↗ “Piperacillin-tazobactam 13.5g over 24h after initial loading dose 2.25g” NCT01667094 ↗ |
| Known as | PIP-TAZ | “4.5 g intravenous (IV) piperacillin-tazobactam (PIP-TAZ) q8h for a fixed 7-day course (no oral switch)” PMID 30861061 ↗ Nov 2019 |
| Known as | Tazocin | “Tazocin” NCT02437045 ↗ |
| Route | Intravenous | “6 doses intravenously” NCT00873327 ↗ |